Erlotinib effective and with fewer side-effects after first-line treatment
Saturday, February 26, 2011 - 05:30
in Health & Medicine
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.